Alli for silhouette restoration 84 capsules 60mg

alli is indicated for weight loss in overweight adults (body mass index, BMI, ≥ 28 kg / m²) and should be taken in conjunction with a moderately low calorie, reduced fat diet.

Technical data sheet (RCP) Excipients:

Ciclosporin A decrease in plasma levels of cyclosporine was observed in a drug interaction study and was also reported in many cases of concomitant administration with orlistat. This could lead to a decrease in the immunosuppressive efficacy of cyclosporine. The concomitant use of alli and cyclosporine is therefore contraindicated (see section 4.3). Oral anticoagulants Administration of warfarin or other oral anticoagulants concomitantly with orlistat may affect the International Normalized Ratio (INR) values (see section 4.8). The concomitant use of alli and warfarin or other oral anticoagulants is therefore contraindicated (see section 4.3). Oral contraceptives The absence of an interaction between oral contraceptives and orlistat has been demonstrated in specific drug interaction studies. However, orlistat may indirectly reduce the availability of oral contraceptives and lead, in some individual cases, to unwanted pregnancy. An additional contraceptive method is recommended in case of severe diarrhea (see section 4.4). Levothyroxine Hypothyroidism and / or impaired control of hypothyroidism may occur when orlistat and levothyroxine are taken simultaneously (see section 4.4). These effects may be due to a reduced absorption of iodine and / or levothyroxine salts. Anti-epileptic drugs There have been reports of convulsions in patients treated concomitantly with orlistat and anti-epileptic drugs, such as eg. valproate, lamotrigine; for such cases a causal relationship due to an interaction cannot be excluded. Orlistat can decrease the absorption of anti-epileptic drugs, leading to seizures. Antiretroviral drugs Based on reports from literature and post-marketing experience, orlistat has the potential to reduce the absorption of HIV antiretroviral drugs and may adversely affect the efficacy of HIV antiretroviral drugs (see section 4.4). Fat-soluble vitamins Therapy with orlistat has the potential to reduce the absorption of fat-soluble vitamins (A, D, E and K). In clinical studies, plasma levels of vitamins A, D, E and K, and beta-carotene remained within the normal range in a large majority of subjects receiving orlistat therapy for up to 4 years. However, patients should be advised to take a multivitamin supplement at bedtime to help ensure adequate vitamin intake (see section 4.4). Acarbose In the absence of pharmacokinetic interaction studies, alli is not recommended in patients treated with acarbose. Amiodarone A decrease in plasma levels of amiodarone, given as a single dose, was observed in a limited number of healthy volunteers treated concomitantly with orlistat. The clinical relevance of this effect in patients receiving amiodarone is still unknown. Patients taking amiodarone should consult their doctor before starting treatment with alli. Amiodarone dose adjustment may be required during treatment with alli. Antidepressants, antipsychotics (including lithium) and benzodiazepines There have been some reports of decreased efficacy of antidepressants, antipsychotics (including lithium) and benzodiazepines in conjunction with initiation of orlistat in previously well-controlled patients. Therefore, treatment with orlistat should only be initiated after careful consideration of the possible effects in these patients.

Technical data sheet (RCP) Composition:

Each hard capsule contains 60 mg of orlistat. For the full list of excipients, see section 6.1.